Vincent Njar is a prominent inventor based in Glen Burnie, MD (US), known for his significant contributions to cancer treatment through innovative pharmaceutical compounds. With a total of 6 patents, Njar has focused on developing novel therapies that target specific cancer pathways, particularly in breast and prostate cancers.

Latest Patents

One of Njar's latest patents involves the development of 13-cis-RAMBA retinamides that degrade MNKs for treating cancer. This patent discusses the synthesis and the in vitro and in vivo anti-breast and anti-prostate cancer activities of novel C-4 heteroaryl 13-cis retinamides. These compounds modulate Mnk-eIF4E and androgen receptor (AR) signaling, leading to the degradation of Mnk1/2 and significantly suppressing eIF4E phosphorylation in both breast and prostate cancer cell lines. Additionally, these compounds induce degradation of both full-length androgen receptor (fAR) and splice variant AR (AR-V7), inhibiting AR transcriptional activity. The multiple activities of these compounds result in the inhibition of cell growth and migration, as well as the induction of apoptosis, demonstrating strong anti-cancer activities with no apparent host toxicities.

Another notable patent focuses on prodrugs of C-17-heteroaryl steroidal CYP17 inhibitors and antiandrogens. This patent describes the synthesis of prodrugs that improve oral bioavailability for compounds that inhibit the human CYP 17 enzyme and act as potent antagonists of both wild type and mutant androgen receptors. These compounds are particularly useful for treating conditions such as human prostate cancer, breast cancer, and prostate hyperplasia.

Career Highlights

Vincent Njar is affiliated with the University System of Maryland, where he continues to advance research in cancer therapeutics. His work has led to significant advancements in understanding how to effectively target cancer pathways, making him a key figure in the field of oncology research.

Collaborations

Njar has collaborated with notable researchers, including Angela Brodie and Lalji K Gediya, to further enhance the impact of his innovations in cancer treatment.

Conclusion

Vincent Njar's innovative work in developing targeted cancer therapies showcases his commitment to improving treatment options for patients. His contributions through multiple patents reflect a significant advancement in

This text is generated by artificial intelligence and may not be accurate.